In ‘sur­prise’ move, BioX­cel files for can­cer sub­sidiary to go pub­lic

BioX­cel is fil­ing for its one-year-old can­cer sub­sidiary to go pub­lic af­ter pre­vi­ous­ly say­ing that it was “ex­plor­ing strate­gic op­tions” for the com­pa­ny in its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER